Abeona Therapeutics Inc. (ABEO) Hits New 52-Week High at $5.72
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $5.72 and last traded at $5.62, with a volume of 377,929 shares changing hands. The stock had previously closed at $5.11.
Several equities analysts recently commented on the company. Zacks Investment Research lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 12th. Cantor Fitzgerald assumed coverage on Abeona Therapeutics in a research note on Wednesday, September 7th. They issued a “buy” rating and a $21.00 target price for the company. Maxim Group set a $6.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 18th. FBR & Co set a $15.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 18th. Finally, Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 target price on shares of Abeona Therapeutics in a research note on Sunday, August 21st. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $12.40.
The stock’s market capitalization is $189.86 million. The company has a 50 day moving average of $4.20 and a 200 day moving average of $3.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/abeona-therapeutics-inc-abeo-hits-new-52-week-high-at-5-72.html
Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Equities research analysts anticipate that Abeona Therapeutics Inc. will post ($0.73) EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of ABEO. Royce & Associates LP raised its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC raised its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares in the last quarter. BlackRock Fund Advisors raised its stake in Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares in the last quarter. Institutional investors own 19.95% of the company’s stock.
Abeona Therapeutics Company Profile
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.